113,188 Shares in Oruka Therapeutics, Inc. $ORKA Purchased by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC acquired a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 113,188 shares of the company’s stock, valued at approximately $10,772,000. Parkman Healthcare Partners LLC owned 0.17% of Oruka Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $28,000. BNP Paribas Financial Markets lifted its stake in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada lifted its stake in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics during the third quarter valued at $39,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $102.42 on Tuesday. Oruka Therapeutics, Inc. has a 1 year low of $14.34 and a 1 year high of $115.51. The stock’s fifty day moving average price is $92.49 and its two-hundred day moving average price is $65.93. The company has a market cap of $6.78 billion, a P/E ratio of -50.45 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, analysts expect that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Carl Dambkowski sold 22,417 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.13, for a total value of $1,572,104.21. Following the sale, the director directly owned 51,326 shares of the company’s stock, valued at approximately $3,599,492.38. This represents a 30.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the transaction, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,633,177.92. This trade represents a 39.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,116 shares of company stock worth $6,636,533 over the last quarter. 23.49% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ORKA has been the subject of a number of recent research reports. UBS Group raised their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Oruka Therapeutics in a report on Monday, August 3rd. Finally, BTIG Research restated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.